Newsmeme!
Discover News you didn't know existed
Students at higher risk of contracting meningitis
Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.
Novartis announced today that Gleevec® tablets* has been granted priority review status by the US Food and Drug Administration as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors .
Hannah's Hope Foundation holds the first ever symposium on GAN.
BERKELEY, CA (UroToday.com) - Organized by the Pain of Urological Origin (PUGO) special interest group of the International Association for the Study of Pain (IASP), Glasgow, Scotland August 15-16, 2008. PUGO held a 2 day meeting in Scotland prior to the IASP 12th World Congress on Pain to consider the past, present and future of urogenital pain.
Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD).
The Association of Racing Commissioners International's board of directors has unanimously approved a drug reclassification of stanozolol, boldenone, nandrolone, and testosterone, moving the anabolic steroids to Class 3 from Class 4. This change in classification clears the way for racing commissions to impose tougher penalties for a positive test consistent with the Model Rules or their ...
The Pain of Urological Origin (PUGO) special interest group of the International Association for the Study of Pain (IASP) held a 2 day meeting in Scotland prior to the IASP 12th World Congress on Pain to consider the past, present and future of urogenital pain. The aim was to outline current practices and have a look at what the future may hold.
ATTENTION EDITOR, GENERAL DESK
Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta® for the treatment of Generalised Anxiety Disorder . This approval -- the fourth for duloxetine in Europe -- was issued on 28 July following an initial positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on 26 June 2008.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |